Article Details

Chemomab claims mid-stage win in NASH - PharmaLive

Retrieved on: 2023-01-04 03:10:15

Tags for this article:

Click the tags to see associated articles and topics

Chemomab claims mid-stage win in NASH - PharmaLive. View article details on hiswai:

Excerpt

CM-101 is a first-in-class monoclonal antibody designed to target the CCL24 protein, a key regulator in fibrotic-inflammatory pathways. The candidate ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up